07.10.19
Manatt’s Ian Spatz, a senior advisor with Manatt Health, spoke with Pink Sheet on a recent federal court ruling concerning drug prices in TV ads.
07.09.19
Manatt’s Ian Spatz, a senior advisor with Manatt Health, spoke with InsideHealthPolicy on a federal court’s decision to block the Trump administration’s proposed rule to include drug prices in television ads for prescription drugs.
05.09.19
Manatt’s Ian Spatz, a senior advisor for Manatt Health, spoke to Axios about the Trump administration’s new rules requiring drugmakers to include prices in TV ads.
03.20.19
Manatt’s Ian Spatz, a senior advisor with Manatt Health, spoke to CNN about partisan disagreements in Congress regarding drug prices.
02.25.19
Manatt’s Ian Spatz, a senior advisor with Manatt Health, spoke with CNBC ahead of a Senate Finance Committee hearing on February 26 in which CEOs from seven of the country’s largest pharmaceutical companies provided testimony about drug pricing in the U.S.
02.01.19
Manatt’s Ian Spatz, a senior advisor with Manatt Health, spoke to FierceHealthcare about the government potentially ending safe-harbor protections for drug rebates in commercial insurance.
01.16.19
Manatt’s Ian Spatz, a senior advisor with our Manatt Health team, discussed with the Sacramento Bee Governor Gavin Newsom’s move to create the largest single purchaser of prescription drugs in the country.
10.26.18
Manatt’s Ian Spatz, a senior advisor with our Manatt Health team, spoke with Kaiser Health News for an article on the Trump administration’s blueprint to upend the healthcare industry.
10.25.18
Manatt’s Ian Spatz, a senior advisor with our Manatt Health team, was interviewed on a PharmaVoice podcast about the effectiveness of the potential drug price transparency requirement.
10.16.18
Manatt’s Ian Spatz, a senior advisor with our Manatt Health team, was interviewed by Bloomberg Law: Health Law & Business for an article on the Trump’s administration’s proposal challenging the pharmaceutical industry.